Chris Allen, CEO of UK-based analytical testing and scientific consultancy provider Broughton, explains the challenges — and opportunities — that Brexit holds for laboratory services.
Key insights:
- Since the end of the Brexit transition period, the UK has continued to accept batch testing results from the EEA and will do so until December 31, 2022.
- In the past, UK manufacturers benefited from funding such as the EMA's Horizon Europe program, but, since Brexit, EU funding has reduced significantly.
- The first COVID-19 vaccines underwent rolling reviews, speeding up patient access compared with other European countries.
Although the UK officially left the European Union (EU) over two and a half years ago, the impact of Brexit is still being felt by Britain's pharmaceutical industry. Since then, we've noticed that areas like Qualified Person (QP), batch release testing and product manufacturing have been impacted. Manufacturers' questions remain unanswered in the absence of a Mutual Recognition Agreement (MRA) between the UK and the EMA that would facilitate market access. .